From Our Partners
Tuesday, June 21, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Preparedness

GAO Says 60 Percent of CBRN National Stockpile Approved for Children

by Global Biodefense Staff
May 2, 2013
GAO Says 60 Percent of CBRN National Stockpile Approved for Children
Pediatric Countermeasures

A report released this week by the U.S. Government Accountability Office (GAO) assesses approximately 60 percent of the chemical, biological, radiological, and nuclear (CBRN) medical countermeasures in the Strategic National Stockpile (SNS) are approved for children, but in many instances approval is limited to specific age groups.

High costs and the high risk of failure associated with testing and research of pharmaceutical products on children, difficulties in meeting regulatory requirements for approving CBRN countermeasures, and scientific and ethical obstacles to safely evaluating countermeasures for children are cited as the predominant challenges to developing pediatric countermeasures for the SNS.

Despite these challenges, the Department of Health and Human Services (HHS) has taken steps to focus agency efforts on the pediatric population, who make up 25 percent of the population in the United States, by adapting pediatric formulations from existing medical countermeasures, and preparing for Emergency Use Authorizations of existing drugs in advance of public health emergencies.

The federal government has also encouraged adapting and manufacturing of oral liquid formulations of existing medical countermeasures in order to ease dispensing of countermeasures in the SNS for children. For example, the Biomedical Advanced Research and Development Authority (BARDA) is contracting with industry partners to manufacture a liquid form of a countermeasure that removes certain radioactive particles from the body through the intestinal tract. 

The report also cast light on countermeasures that have not technically been approved to treat individuals for the specific indications for which they have been stockpiled. For example, ciprofloxacin is stockpiled in the SNS for the treatment of anthrax, plague, and tularemia, but is not approved for these indications. Countermeasures may be used to treat unapproved age groups or indications under an emergency use authorization (EUA) or an Investigational New Drug (IND) application submitted to the Food and Drug Administration (FDA).

Federal and state-level emergency response planning for dispensing of pediatric medical countermeasures were also examined for the GAO report. Plans for the state and local governments that GAO reviewed included details about dispensing to the pediatric population during an emergency, often having adopted some version of a “head of household” policy that would allow adults to pick up medicines for other family members, including children, during an event.

The full report is available at the GAO website: National Preparedness – Efforts to Address the Medical Needs of Children in a Chemical, Biological, Radiological or Nuclear Incident (.pdf)

From Our Partners
Tags: AnthraxASPRBARDAEmergency Use AuthorizationHHSStrategic National StockpileY. pestis

Related Posts

BARDA and JPEO-CBRND Back Cepheid’s Multiplex Test for Influenza, SARS-CoV2 and RSV
Health Security

Resurgent COVID-19, Flu and Other Viruses are Pushing New Zealand’s Health System to the Limit

June 2, 2022
Politics and Pandemic Fatigue Doom California’s Covid Vaccine Mandates
Public Health

Politics and Pandemic Fatigue Doom California’s Covid Vaccine Mandates

May 31, 2022
Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster
Preparedness

Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

May 6, 2022
masked medical laboratory technician waits on samples to process in a biocontainment lab
Biosecurity

Design Phase Kicks Off for New $750M Wadsworth Public Health Laboratory

May 1, 2022
Load More

Latest News

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Biodefense Headlines – 16 June 2022

Biodefense Headlines – 16 June 2022

June 16, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC